Regulatory approval

Published by the Health Canada. Approved

GLEEVEC (imatinib mesylate) is indicated for the treatment of adult patients with myelodysplastic/myeloproliferative diseases (MDS/MPD) associated with platelet-derived growth factor receptor (PDGFR) gene re-arrangements.

This is written in the approval document.

Citation

Novartis Pharmaceuticals Canada Inc. Gleevec (imatinib) [product monograph]. Health Canada website. https://pdf.hres.ca/dpd_pm/00083190.PDF. Revised January 2026. Accessed April 2026.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
HC (1)	PDGFRA rearrangements	Myelodysplastic Syndromes	Imatinib
HC (1)	PDGFRB rearrangements	Myelodysplastic Syndromes	Imatinib
HC (1)	PDGFRA rearrangements	Myeloproliferative Neoplasm	Imatinib
HC (1)	PDGFRB rearrangements	Myeloproliferative Neoplasm	Imatinib